Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Change in Accured Expenses of -$86.0 million for Q1 2026, down 206.17% year-over-year from $81.0 million in Q1 2025, and down 975.0% quarter-over-quarter from -$8.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$86.0 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 206.17% year-over-year to -$86.0 million; the TTM figure through Mar 2026 stood at -$126.0 million (down 241.57% YoY), while the FY2025 annual figure was $41.0 million, up 412.5% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$86.0 million, down from -$8.0 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $81.0 million in Q1 2025, with the low at -$86.0 million in Q1 2026.
- The 3-year median for Change in Accured Expenses is $1.0 million (2024), against an average of -$4.6 million.
- Peak annual rise in Change in Accured Expenses reached 87.3% in 2025, while the deepest fall reached 920.0% in 2025.
- Indivior Pharmaceuticals' Change in Accured Expenses stood at -$63.0 million in 2024, then soared by 87.3% to -$8.0 million in 2025, then sank by 975.0% to -$86.0 million in 2026.
- Business Quant data shows INDV's Change in Accured Expenses at -$86.0 million in Q1 2026, -$8.0 million in Q4 2025, and -$82.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | 73.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.00 Mn |
| Jun 30, 2026 | 73.00 Mn |
| Mar 31, 2026 | -86.00 Mn |
| Mar 31, 2026 | -86.00 Mn |
| Dec 31, 2025 | -8.00 Mn |
| Dec 31, 2025 | -8.00 Mn |
| Sep 30, 2025 | -82.00 Mn |
| Sep 30, 2025 | -82.00 Mn |
| Jun 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 50.00 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | -63.00 Mn |
| Dec 31, 2024 | -63.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 61.00 Mn |
| Jun 30, 2024 | 61.00 Mn |